Sponsored

Angeles Alvarez Secord, MD, MHSc, discusses the importance of genetic testing and tumor testing in ovarian cancer and the potential impact on treatment decisions.

Gary Fanjiang, MD, vice president of Biosimilars Global Development, Amgen, discusses the development of biosimilars and some of the clinical considerations related to their use.

New data presented at this year’s American Society of Hematology Annual Meeting showed that adding DARZALEX® (daratumumab) to standard of care multiple myeloma therapies may extend survival and achieve levels of minimal residual disease not previously seen.

Advancing cancer care requires more than just science. It’s a collective effort driven by passionate individuals and organizations dedicated to making a difference for those living with and affected by cancer.

Investigators are optimistic that LN-145, an autologous tumor-infiltrating lymphocyte investigational therapy, could be a potential treatment option for patients with recurrent, metastatic, or persistent cervical cancer.

While there are efforts underway to address the significant unmet need for treatments at every stage of the lung cancer continuum, there has been rapid progress in NSCLC.

Lilly hosted an immersive and interactive reception during the 2018 Gastrointestinal Cancers Symposium entitled,

Since the approval of LYNPARZA, over 3,000 US women with germline BRCA-mutated advanced ovarian cancer have been treated with this important medicine.

Immuno-oncology is among the most discussed topics in cancer research, but many are unaware of the science behind this class of treatments. Learn how it works.